The Phase 3 ABTECT trials (Studies 105 and 106) evaluating obefazimod in patients with moderately to severely active ulcerative colitis successfully enrolled 1,275 participants, exceeding the target ...

A Phase I trial involving ten patients with relapsed or refractory classical Hodgkin lymphoma or T-cell lymphoma has achieved ...

NanoViricides, Inc. (NYSE American: NNVC) provided an update on its Measles drug development program, highlighting the potential of its broad-spectru ...

THERANEXUS - THERANEXUS PUBLISHES ITS 2024 FULL-YEAR RESULTS, PRESENTS ITS PROGRESS REPORT AND CLOSES ITS EQUITY LINE ...

Prilenia CEO Dr. Hayden purchased the development rights in exchange for limited future royalties and founded Prilenia ...

INX-315, a CDK2 inhibitor, received FDA fast track designation for patients with CCNE1-amplified platinum-resistant ovarian ...

Updated Phase 3 analyses position PL9643 as a potential first-in-class therapy achieving full symptom resolution in dry eye disease. <li ...

Detailed price information for Fate Therapeutics (FATE-Q) from The Globe and Mail including charting and trades.

Acousia Therapeutics GmbH announced that it has successfully enrolled 50% of patients in its ongoing Phase 2 clinical trial, the PROHEAR Study, evaluating ACOU085 (INN: bimokalner) for the prevention ...

Discover six hemophilia companies developing new treatments for the genetic bleeding disorder, from gene therapies to RNAi therapies.